Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC, and UCHL1.

Heitzer, E; Artl, M; Filipits, M; Resel, M; Graf, R; Weißenbacher, B; Lax, S; Gnant, M; Wrba, F; Greil, R; Dietze, O; Hofbauer, F; Böhm, G; Höfler, G; Samonigg, H; Schaberl-Moser, R; Balic, M; Dandachi, N; Mod Pathol. 2014; 27(6): 906-915.

Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia.

Gassner, FJ; Zaborsky, N; Neureiter, D; Huemer, M; Melchardt, T; Egle, A; Rebhandl, S; Catakovic, K; Hartmann, TN; Greil, R; Geisberger, R; Haematologica. 2014; 99(5):67-69

Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival.

Pleyer, L; Germing, U; Sperr, WR; Linkesch, W; Burgstaller, S; Stauder, R; Girschikofsky, M; Schreder, M; Pfeilstocker, M; Lang, A; Sliwa, T; Geissler, D; Schlick, K; Placher-Sorko, G; Theiler, G; Thaler, J; Mitrovic, M; Neureiter, D; Valent, P; Greil, R; Leuk Res. 2014; 38(4):475-483

Human immunodeficiency virus type 2 infections in Austria.

Taylor, N; Kern, JM; Prammer, W; Lang, A; Haas, B; Gisinger, M; Zangerle, R; Egle, A; Greil, R; Oberkofler, H; Eberle, J; Wien Klin Wochenschr. 2014; 126(7-8):212-216

Targeting proliferation of chronic lymphocytic leukemia (CLL) cells through KCa3.1 blockade.

Grössinger, EM; Weiss, L; Zierler, S; Rebhandl, S; Krenn, PW; Hinterseer, E; Schmölzer, J; Asslaber, D; Hainzl, S; Neureiter, D; Egle, A; Piñón-Hofbauer, J; Hartmann, TN; Greil, R; Kerschbaum, HH; Leukemia. 2014; 28(4):954-958

Liver toxicity during temozolomide chemotherapy caused by Chinese herbs.

Melchardt, T; Magnes, T; Weiss, L; Grundbichler, M; Strasser, M; Hufnagl, C; Moik, M; Greil, R; Egle, A; BMC COMPLEM ALTERN M. 2014; 14: 115

Prognostic significance of Ki67 proliferation index, HIF1 alpha index and microvascular density in patients with non-small cell lung cancer brain metastases.

Berghoff, AS; Ilhan-Mutlu, A; Wöhrer, A; Hackl, M; Widhalm, G; Hainfellner, JA; Dieckmann, K; Melchardt, T; Dome, B; Heinzl, H; Birner, P; Preusser, M; Strahlenther Onkol. 2014; 190(7):676-685

Pleural decortication of a marginal zone lymphoma.

Melchardt, T; Weiss, L; Namberger, K; Pretsch, I; Hutter, J; Rettenbacher, L; Neureiter, D; Troch, M; Greil, R; Egle, A; Ann Hematol. 2014; 93(7):1253-1254

Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24).

Steger, GG; Greil, R; Lang, A; Rudas, M; Fitzal, F; Mlineritsch, B; Hartmann, BL; Bartsch, R; Melbinger, E; Hubalek, M; Stoeger, H; Dubsky, P; Ressler, S; Petzer, AL; Singer, CF; Muss, C; Jakesz, R; Gampenrieder, SP; Zielinski, CC; Fesl, C; Gnant, M; Ann Oncol. 2014; 25(2):366-371

The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer.

Filipits, M; Nielsen, TO; Rudas, M; Greil, R; Stoger, H; Jakesz, R; Bago-Horvath, Z; Dietze, O; Regitnig, P; Gruber-Rossipal, C; Muller-Holzner, E; Singer, CF; Mlineritsch, B; Dubsky, P; Bauernhofer, T; Hubalek, M; Knauer, M; Trapl, H; Fesl, C; Schaper, C; Ferree, S; Liu, SZ; Cowens, JW; Gnant, M CLIN CANCER RES. 2014; 20(5): 1298-1305.